Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea — Rifaximin 600

Travelers' Diarrhea Clinical Trial

Official title:
Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea

Status Withdrawn

Clinical Trial Summary

The study will compare durations of diarrhea among subjects who report to clinic for treatment and who receive either:

1. standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, OR

2. a single 600 mg dose of rifaximin daily for 3 days.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00875875
Study type	Interventional
Source	The University of Texas Health Science Center, Houston
Contact
Status	Withdrawn
Phase	Phase 4
Start date	June 2009
Completion date	June 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00564863` - Dose-Finding Study of CS19 Expressing ETEC Challenge Strains	Phase 1
Completed	`NCT00564577` - Dose-Finding Study of WS6788A and LSN03-016011/A Enterotoxigenic E. Coli ETEC Challenge Strains That Express CS17	Phase 1
Terminated	`NCT01005849` - Probiotics and the Prevention of Traveler's Diarrhea	Phase 4
Completed	`NCT00993681` - Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study	Phase 3
Completed	`NCT02498301` - Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD	N/A
Completed	`NCT00292344` - Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea	Phase 4
Completed	`NCT00524004` - Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD	Phase 2
Terminated	`NCT02920242` - A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.	Phase 3